Literature DB >> 26628006

Dysregulation of microRNA biogenesis machinery in cancer.

Akiko Hata1, Risa Kashima1.   

Abstract

MicroRNAs (miRNAs) are integral to the gene regulatory network. A single miRNA is capable of controlling the expression of hundreds of protein coding genes and modulate a wide spectrum of biological functions, such as proliferation, differentiation, stress responses, DNA repair, cell adhesion, motility, inflammation, cell survival, senescence and apoptosis, all of which are fundamental to tumorigenesis. Overexpression, genetic amplification, and gain-of-function mutation of oncogenic miRNAs ("onco-miRs") as well as genetic deletion and loss-of-function mutation of tumor suppressor miRNAs ("suppressor-miRs") are linked to human cancer. In addition to the dysregulation of a specific onco-miR or suppressor-miRs, changes in global miRNA levels resulting from a defective miRNA biogenesis pathway play a role in tumorigenesis. The function of individual onco-miRs and suppressor-miRs and their target genes in cancer has been described in many different articles elsewhere. In this review, we primarily focus on the recent development regarding the dysregulation of the miRNA biogenesis pathway and its contribution to cancer.

Entities:  

Keywords:  Argonaute; DGCR8; Dicer; Drosha; TRBP; microRNA; post-translational modifications; pre-miRNA; pri-miRNA; processing; stability

Mesh:

Substances:

Year:  2015        PMID: 26628006      PMCID: PMC5226641          DOI: 10.3109/10409238.2015.1117054

Source DB:  PubMed          Journal:  Crit Rev Biochem Mol Biol        ISSN: 1040-9238            Impact factor:   8.250


  113 in total

1.  DICER1 exons 25 and 26 mutations are rare in common human tumours besides Sertoli-Leydig cell tumour.

Authors:  Min S Kim; Sung H Lee; Nam J Yoo; Sug H Lee
Journal:  Histopathology       Date:  2013-06-13       Impact factor: 5.087

2.  Hippo signaling regulates microprocessor and links cell-density-dependent miRNA biogenesis to cancer.

Authors:  Masaki Mori; Robinson Triboulet; Morvarid Mohseni; Karin Schlegelmilch; Kriti Shrestha; Fernando D Camargo; Richard I Gregory
Journal:  Cell       Date:  2014-02-27       Impact factor: 41.582

3.  Expression levels of the microRNA processing enzymes Drosha and dicer in epithelial skin cancer.

Authors:  Michael Sand; Thilo Gambichler; Marina Skrygan; Daniel Sand; Nina Scola; Peter Altmeyer; Falk G Bechara
Journal:  Cancer Invest       Date:  2010-07       Impact factor: 2.176

4.  Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers.

Authors:  Alireza Heravi-Moussavi; Michael S Anglesio; S-W Grace Cheng; Janine Senz; Winnie Yang; Leah Prentice; Anthony P Fejes; Christine Chow; Alicia Tone; Steve E Kalloger; Nancy Hamel; Andrew Roth; Gavin Ha; Adrian N C Wan; Sarah Maines-Bandiera; Clara Salamanca; Barbara Pasini; Blaise A Clarke; Anna F Lee; Cheng-Han Lee; Chengquan Zhao; Robert H Young; Samuel A Aparicio; Poul H B Sorensen; Michelle M M Woo; Niki Boyd; Steven J M Jones; Martin Hirst; Marco A Marra; Blake Gilks; Sohrab P Shah; William D Foulkes; Gregg B Morin; David G Huntsman
Journal:  N Engl J Med       Date:  2011-12-21       Impact factor: 91.245

Review 5.  Alternative miRNA biogenesis pathways and the interpretation of core miRNA pathway mutants.

Authors:  Jr-Shiuan Yang; Eric C Lai
Journal:  Mol Cell       Date:  2011-09-16       Impact factor: 17.970

6.  DNA-damage-induced nuclear export of precursor microRNAs is regulated by the ATM-AKT pathway.

Authors:  Guohui Wan; Xinna Zhang; Robert R Langley; Yunhua Liu; Xiaoxiao Hu; Cecil Han; Guang Peng; Lee M Ellis; Stephen N Jones; Xiongbin Lu
Journal:  Cell Rep       Date:  2013-06-20       Impact factor: 9.423

7.  Dicer, Drosha, and outcomes in patients with ovarian cancer.

Authors:  William M Merritt; Yvonne G Lin; Liz Y Han; Aparna A Kamat; Whitney A Spannuth; Rosemarie Schmandt; Diana Urbauer; Len A Pennacchio; Jan-Fang Cheng; Alpa M Nick; Michael T Deavers; Alexandra Mourad-Zeidan; Hua Wang; Peter Mueller; Marc E Lenburg; Joe W Gray; Samuel Mok; Michael J Birrer; Gabriel Lopez-Berestein; Robert L Coleman; Menashe Bar-Eli; Anil K Sood
Journal:  N Engl J Med       Date:  2008-12-18       Impact factor: 91.245

8.  Distinct microRNA alterations characterize high- and low-grade bladder cancer.

Authors:  James W F Catto; Saiful Miah; Helen C Owen; Helen Bryant; Katie Myers; Ewa Dudziec; Stéphane Larré; Marta Milo; Ishtiaq Rehman; Derek J Rosario; Erica Di Martino; Margaret A Knowles; Mark Meuth; Adrian L Harris; Freddie C Hamdy
Journal:  Cancer Res       Date:  2009-10-20       Impact factor: 12.701

9.  Pituitary blastoma: a pathognomonic feature of germ-line DICER1 mutations.

Authors:  Leanne de Kock; Nelly Sabbaghian; François Plourde; Archana Srivastava; Evan Weber; Dorothée Bouron-Dal Soglio; Nancy Hamel; Joon Hyuk Choi; Sung-Hye Park; Cheri L Deal; Megan M Kelsey; Megan K Dishop; Adam Esbenshade; John F Kuttesch; Thomas S Jacques; Arie Perry; Heinz Leichter; Philippe Maeder; Marie-Anne Brundler; Justin Warner; James Neal; Margaret Zacharin; Márta Korbonits; Trevor Cole; Heidi Traunecker; Thomas W McLean; Fabio Rotondo; Pierre Lepage; Steffen Albrecht; Eva Horvath; Kalman Kovacs; John R Priest; William D Foulkes
Journal:  Acta Neuropathol       Date:  2014-05-20       Impact factor: 17.088

10.  The RNA-binding protein KSRP promotes the biogenesis of a subset of microRNAs.

Authors:  Michele Trabucchi; Paola Briata; Mariaflor Garcia-Mayoral; Astrid D Haase; Witold Filipowicz; Andres Ramos; Roberto Gherzi; Michael G Rosenfeld
Journal:  Nature       Date:  2009-05-20       Impact factor: 49.962

View more
  58 in total

1.  MiR-501-5p acts as an energetic regulator in head and neck squamous cell carcinoma cells growth and aggressiveness via reducing CLCA4.

Authors:  Bo Li; Yuan-Pei Jiang; Jie Zhu; Lei Meng
Journal:  Mol Biol Rep       Date:  2020-02-19       Impact factor: 2.316

Review 2.  Regulation of breast cancer metastasis signaling by miRNAs.

Authors:  Belinda J Petri; Carolyn M Klinge
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

Review 3.  Roles of miRNA and lncRNA in triple-negative breast cancer.

Authors:  Juan Xu; Kang-Jing Wu; Qiao-Jun Jia; Xian-Feng Ding
Journal:  J Zhejiang Univ Sci B       Date:  2020 Sept.       Impact factor: 3.066

4.  miRNA biogenesis-associated RNase III nucleases Drosha and Dicer are upregulated in colorectal adenocarcinoma.

Authors:  Shin Kim; Mei Ling Song; Hyeonji Min; Ilseon Hwang; Seong Kyu Baek; Taeg Kyu Kwon; Jong-Wook Park
Journal:  Oncol Lett       Date:  2017-07-26       Impact factor: 2.967

5.  G-Quadruplexes influence pri-microRNA processing.

Authors:  Samuel G Rouleau; Jean-Michel Garant; François Bolduc; Martin Bisaillon; Jean-Pierre Perreault
Journal:  RNA Biol       Date:  2017-12-11       Impact factor: 4.652

6.  MicroRNA-31 inhibits RhoA-mediated tumor invasion and chemotherapy resistance in MKN-45 gastric adenocarcinoma cells.

Authors:  Alireza Korourian; Raheleh Roudi; Ahmad Shariftabrizi; Zahra Madjd
Journal:  Exp Biol Med (Maywood)       Date:  2017-08-24

7.  miR-26a inhibits the proliferation of ovarian cancer cells via regulating CDC6 expression.

Authors:  Ting-Yi Sun; Hong-Jian Xie; Hui He; Zhen Li; Ling-Fei Kong
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

Review 8.  Non-viral based miR delivery and recent developments.

Authors:  Annalise Elizabeth Labatut; George Mattheolabakis
Journal:  Eur J Pharm Biopharm       Date:  2018-04-19       Impact factor: 5.571

9.  miR-34a regulates HDAC1 expression to affect the proliferation and apoptosis of hepatocellular carcinoma.

Authors:  Ting-Yi Sun; Hong-Jian Xie; Zhen Li; Ling-Fei Kong; Xiang-Nan Gou; Du-Juan Li; Yu-Jie Shi; Yan-Zhi Ding
Journal:  Am J Transl Res       Date:  2017-01-15       Impact factor: 4.060

Review 10.  Colorectal Cancer: From the Genetic Model to Posttranscriptional Regulation by Noncoding RNAs.

Authors:  María Antonia Lizarbe; Jorge Calle-Espinosa; Eva Fernández-Lizarbe; Sara Fernández-Lizarbe; Miguel Ángel Robles; Nieves Olmo; Javier Turnay
Journal:  Biomed Res Int       Date:  2017-05-10       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.